Viewing data from:

MARLISSA

ANDA

ETHINYL ESTRADIOL; LEVONORGESTREL | A091452 | GLENMARK PHARMACEUTICALS LTD

1 strength0 unique patents0 unique exclusivities

Medicare Part D Spending

CMS annual spending data for Marlissa (2023)

Total Spending

$33K

Total Claims

1,320

Beneficiaries

338

Avg Cost/Unit

$0.41

Spending Trend

$76K(2019)→$59K(2020)→$47K(2021)→$37K(2022)→$33K(2023)

YoY Change:-9.6%

5yr CAGR:-5.7%

Source: CMS Medicare Part D Spending by Drug (2023). Shows gross drug cost under Part D.

Products (1)

#001 — 0.03MG;0.15MG

0 patents0 exclusivities▴

TABLET;ORAL-28 | Approved: Feb 29, 2012

No patent or exclusivity listings for this strength.